ArticleJournal of clinical practice and research2025
Investigation of the Protective Effect of Betaine in an Experimental Pulmonary Fibrosis Model Induced by Intratracheal Administration of Bleomycin.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pulmonary fibrosis is a progressive and fatal disease that is commonly seen in the general population, with an etiology and treatment methods that have not yet been fully elucidated. Intratracheal bleomycin (BLE) administration is one of the most common experimental models used to create pulmonary fibrosis. Betaine is a natural compound with proven antioxidant and anti-inflammatory properties. In the present study, the protective role of betaine against pulmonary fibrosis induced by intratracheal administration of bleomycin was investigated. Materials and Methods: Four different groups were formed for the present study (n=7): Control, BLE, Betaine, and BLE+Betaine. BLE was given as a single dose on the first day of the experiment. The betaine application was given for 14 days, starting simultaneously with BLE, once a day. No application was made between days 14-21, and the experiment was completed on day 21. The lung tissues obtained were investigated using histopathological, immunohistochemical, and biochemical methods. Results: BLE was found to trigger parenchymal fibrosis and the accompanying inflammatory response. Betaine tended to reduce these effects. Immunohistochemically evaluated α-SMA, MMP8, TGF-β, and IFN-ɣ increased due to BLE and tended to decrease in the BLE+Betaine group. There was no significant difference between the groups for IL-1β and IL-6. Galectin-3, hydroxyproline, and collagen type I, evaluated by ELISA, increased due to BLE and showed a decreasing trend in the BLE+Betaine group. Conclusion: In conclusion, we believe that betaine tends to reduce the progression of bleomycin-induced fibrosis and that research should be continued to support current treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.